Background Impairment in a wide range of cognitive abilities has been consistently reported
in individuals with schizophrenia. Both neurocognitive and social cognitive deficits are …

In 2014, two groups of scientists published open letters on the efficacy of brain-training
interventions, or “brain games,” for improving cognition. The first letter, a consensus …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

Objective: Many psychotropic medications used to treat schizophrenia have significant
anticholinergic properties, which are linked to cognitive impairment and dementia risk in …

Antipsychotic drugs (APDs) are best classified as typical or atypical. The distinction is based
solely on their ability to cause extrapyramidal side effects (EPS), including tardive dyskinesia …

Although schizophrenia is an illness that has been historically characterized by the
presence of positive symptomatology, decades of research highlight the importance of …

OBJECTIVE: To assess the prevalence and correlates of antipsychotic polypharmacy (APP)
across decades and regions. METHODS: Electronic PubMed/Google Scholar search for …

These guidelines from the British Association for Psychopharmacology address the scope
and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving …

Introduction Drug-induced parkinsonism (DIP) and tardive dyskinesia (TD) are stigmatizing
movement disorders associated with exposure to dopamine receptor blocking agents such …

Introduction: Anticholinergics are a class of medicines that block the neurotransmitter,
acetylcholine, in the brain and peripheral tissues. Medicines with anticholinergic activity are …